InvestSMART

Cogstate Limited (ASX: CGS) - Announcements

Current share price for CGS : $3.370 0.02 (0.59%)+

ASX company news and announcements for Cogstate Limited (CGS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cogstate Limited (CGS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cogstate Limited (CGS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cogstate Limited (CGS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$582 Appendix 4D and Half-Year Financial Report 18 Feb 2014 3:18PM $0.385 $3.370 risen by 775.32%
$582 Cogstate Test to be used in large paediatric clinical trial 12 Feb 2014 10:26AM $0.370 $3.370 risen by 810.81%
$582 Appendix 4C - quarterly 28 Jan 2014 3:42PM $0.350 $3.370 risen by 862.86%
$582 Cogstate Awarded Tender 23 Dec 2013 9:59AM $0.360 $3.370 risen by 836.11%
$582 Rights Issue Offer Document 3 Dec 2013 10:32AM $0.390 $3.370 risen by 764.10%
$582 Fully Underwritten Non-Renounceable Rights Issue / Placement 19 Nov 2013 8:45AM $0.390 $3.370 risen by 764.10%
$582 Business Update and First Half Financial Guidance 19 Nov 2013 8:40AM $0.390 $3.370 risen by 764.10%
$582 Trading Halt 18 Nov 2013 9:48AM $0.450 $3.370 risen by 648.89%
$582 AGM Presentation slides 23 Oct 2013 3:27PM $0.530 $3.370 risen by 535.85%
$582 30 Sep 2013 Business Update and Appendix 4C 23 Oct 2013 3:27PM $0.530 $3.370 risen by 535.85%
$582 Merck releases new data on effectiveness of Cognigram 8 Oct 2013 10:35AM $0.475 $3.370 risen by 609.47%
$582 Growing recognition of Cogstate test as a cognitive tool 26 Sep 2013 9:24AM $0.460 $3.370 risen by 632.61%
$582 Appendix 4E and Preliminary Final Report 21 Aug 2013 9:38AM $0.420 $3.370 risen by 702.38%
$582 Quarterly Business Update and Cashflow - 30 June 2013 29 Jul 2013 2:30PM $0.320 $3.370 risen by 953.13%
$582 Appendix 4C - quarterly 29 Jul 2013 2:30PM $0.320 $3.370 risen by 953.13%
$582 Cogstate selected for Alzheimers disease preventation trial 23 May 2013 9:25AM $0.360 $3.370 risen by 836.11%
$582 Business Update 24 Apr 2013 1:41PM $0.370 $3.370 risen by 810.81%
$582 Appendix 4C - quarterly 24 Apr 2013 1:41PM $0.370 $3.370 risen by 810.81%
$582 CogState launches Cognigram test in Canada 6 Mar 2013 9:46AM $0.380 $3.370 risen by 786.84%
$582 Half Yearly Report and Accounts 20 Feb 2013 9:58AM $0.350 $3.370 risen by 862.86%
$582 Appendix 4C - quarterly 21 Jan 2013 9:58AM $0.350 $3.370 risen by 862.86%
$582 Business Update 21 Jan 2013 9:58AM $0.350 $3.370 risen by 862.86%
$582 Chairman & CEO's AGM speech 16 Oct 2012 12:41PM $0.400 $3.370 risen by 742.50%
$582 CogState tests helping to detect Alzheimer's disease 16 Oct 2012 9:05AM $0.400 $3.370 risen by 742.50%
$582 Appendix 4C - quarterly 12 Oct 2012 12:27PM $0.350 $3.370 risen by 862.86%

876 - 900 of 1013 results

Page 36 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.